ReviewThe Journal of frailty & aging2019
Development of Pharmacotherapies for the Treatment of Sarcopenia.
Review in The Journal of frailty & aging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Exercise interventions of ≥8 weeks improve body composition, physical function, metabolism, and inflammation in older adults with stageFrontiers in nutrition · 2025Pooled it
- Bimagrumab vs Optimized Standard of Care for Treatment of Sarcopenia in Community-Dwelling Older Adults: A Randomized Clinical Trial.JAMA network open · 2020Trial
- Review
- Probiotic Bifidobacterium animalis subsp. lactis DS109-B11 ameliorates age-related muscle weakness via AMPK activation.Scientific reports · 2026Article
- The therapeutic potential of Myoki, a novel peptide in muscle atrophy: mechanisms and applications.Frontiers in pharmacology · 2026Article
- Kampo medicine as a nutrition-relevant multi-target intervention for sarcopenia: implications for appetite, mitochondrial function, and the frailty-sarcopenia-cachexia continuum.Frontiers in nutrition · 2026Review
- A Liposomal Strategy for Dual-Action Therapy in Sarcopenia: Co-Delivery of Caffeine and HAMA.International journal of molecular sciences · 2025Article
- DMPC-Based Liposomal Vesicles for Encapsulation and Controlled Release of NMN and Matrigel in Sarcopenia Therapy.International journal of molecular sciences · 2025Article
- Electroacupuncture treatment for sarcopenia: study protocol for a randomized controlled trial.BMC complementary medicine and therapies · 2024Article
- Gaining muscle mass in COPD: a work in progress.ERJ open research · 2023Article
- A Phase 1 study for safety and pharmacokinetics of BIO101 (20-hydroxyecdysone) in healthy young and older adults.Journal of cachexia, sarcopenia and muscle · 2023Article
- Sarcopenia in Rheumatoid arthritis. A narrative review.Journal of frailty, sarcopenia and falls · 2023Review
- Frailty in older people living with HIV: current status and clinical management.BMC geriatrics · 2022Review
- Editorial: The relationship between sarcopenia and metabolic diseases: Its formation mechanism and intervention means.Frontiers in endocrinology · 2022Article
- Screening, Diagnosis and Management of Sarcopenia and Frailty in Hospitalized Older Adults: Recommendations from the Australian and New Zealand Society for Sarcopenia and Frailty Research (ANZSSFR) Expert Working Group.The journal of nutrition, health & aging · 2022Review
- DXA-Derived Indices in the Characterisation of Sarcopenia.Nutrients · 2021Observational
- A Bioassay-Guided Fractionation of Rosemary Leaf Extract Identifies Carnosol as a Major Hypertrophy Inducer in Human Skeletal Muscle Cells.Nutrients · 2021Article
- Sarcopenia versus cancer cachexia: the muscle wasting continuum in healthy and diseased aging.Biogerontology · 2021Review
- Myostatin and Follistatin-New Kids on the Block in the Diagnosis of Sarcopenia in IBD and Possible Therapeutic Implications.Biomedicines · 2021Review
- Update on the ESCEO recommendation for the conduct of clinical trials for drugs aiming at the treatment of sarcopenia in older adults.Aging clinical and experimental research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcopenia, the associated loss of skeletal muscle mass and strength and impaired physical function seen with aging, is a growing, global public health challenge in need of accepted, proven treatments that address the needs of a broad range of older adults. While exercise, primarily resistance training, and increased dietary protein have been shown to delay and even reverse losses in muscle mass, strength and physical function seen with aging, proven treatments that are accessible globally, cost effective and sustainable by patients are needed. While no drug has yet demonstrated the substantial safety and clinical value needed to be the first pharmacological therapy registered for muscle wasting or sarcopenia, the field is active. Several approaches to treating the muscle loss and subsequent functional decline are being studied in a variety of patient populations across every continent. We provide a review of the leading programs and approaches and available findings from recent studies. In addition, we briefly discuss several related issues needed to facilitate the development of a safe and efficacious pharmacotherapeutic that could be used as part of a treatment plan for older men and women with sarcopenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.